Qantas Airways (ASX: QAN) shares have been in focus again as Project Sunrise edges closer to reality.

The airline recently unveiled its first purpose-built Airbus A350-1000ULR in Toulouse, France.

Non-stop flights from Sydney to London are now locked in for October 2027, with tickets going on sale from February 2027.

A Sydney to New York route will follow, though a launch date has not yet been confirmed.

What is the new aircraft?

The new aircraft will carry just 238 passengers, well down on the 410 seats found on a standard A350. This will make room for extra fuel tanks and a dedicated wellbeing zone.

Qantas has ordered 12 of the ultra-long-range jets in total.

Management says the intent to book a Project Sunrise flight has climbed sharply among premium leisure travellers since February 2026.

This is a promising signal for a product built around high-margin cabins.

So where does that leave Qantas shares?

Qantas shares are trading on a price to earnings ratio of around 10 times, below the global airline industry average of roughly 9 to 12 times depending on the peer set used.

The stock carries a dividend yield near 3.5%, with the payout covered by earnings.

Analyst sentiment remains firmly positive.

Multiple brokers rate Qantas a buy or outperform, with average 12-month price targets clustering between roughly $11 and $12.

That implies modest to solid upside from current levels, though estimates vary depending on each analyst’s fuel and demand assumptions.

The bull and bear case for Qantas shares

The bull case rests on Qantas converting its domestic duopoly position, its loyalty program, and Project Sunrise into durable earnings growth over the next several years.

The bear case is the one that has dogged all airlines recently.

Fuel costs have risen sharply on the back of the conflict involving Iran, and Qantas has flagged higher near-term jet fuel bills as a result.

Airlines are also inherently cyclical, and a downturn in travel demand can hit margins quickly.

Project Sunrise itself has already been delayed roughly six months from its original schedule, a reminder that execution risk on a genuinely novel aircraft program is real.

For investors comfortable with cyclical risk, Qantas offers a rare combination of a reasonable valuation, a growing loyalty and freight business, and a marquee growth catalyst in Project Sunrise that could open a new premium revenue stream from 2027.

For more conservative investors, the fuel cost backdrop and the airline’s history of guidance resets are worth weighing carefully before buying.

Foolish Takeaway

Project Sunrise gives Qantas a new growth catalyst heading into 2027.

The shares still trade at an undemanding multiple relative to the broader airline sector.

But investors should size any position with the industry’s fuel and demand cyclicality firmly in mind.

The post Project Sunrise incoming: Are Qantas shares a buy? appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Netwealth, Silver Mines, and Qantas shares
• Buy, hold or sell, PEXA, ASX and Qantas shares
• How much do I need in my superannuation to get $6,000 per month in passive income?
• 5 things to watch on the ASX 200 on Tuesday
• How Qantas shares soared ahead of the ASX 200 in June

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

A 10-year investment period gives investors time to think beyond the next market wobble.

With $20,000, ASX exchange traded funds (ETFs) can provide exposure to global quality companies, robotics and artificial intelligence, and China’s consumer and technology economy.

Here are three ASX ETFs that could be top long-term picks.

Betashares Global Quality Leaders ETF (ASX: QLTY)

The Betashares Global Quality Leaders ETF could be worth considering.

This ASX ETF is designed to provide exposure to global companies with quality characteristics. That can include strong profitability, solid balance sheets, and earnings that have shown a degree of resilience over time.

The idea is not to chase the most exciting theme in the market. It is to own companies that have already proven they can make money at a high level and keep doing so through different conditions.

That can be important over a 10-year period because markets never move in a straight line. There will be recessions, inflation scares, rate changes, earnings downgrades, and plenty of volatility along the way.

A quality-focused fund can help anchor the portfolio with businesses that have the financial strength to keep investing, defend margins, and compound over time. It was recently recommended by the team at Betashares.

Betashares Global Robotics and Artificial Intelligence ETF (ASX: RBTZ)

Another ASX ETF to look at is the Betashares Global Robotics and Artificial Intelligence ETF.

This fund gives investors exposure to companies involved in robotics, automation, artificial intelligence, drones, unmanned vehicles, and related technologies. That makes it a more targeted growth holding.

The long-term case is tied to how work is changing. Factories, warehouses, hospitals, farms, logistics networks, and transport systems are all looking for ways to become more efficient, precise, and automated.

Robotics is not just about humanoid machines. It can include industrial equipment, sensors, robotic surgery tools, autonomous systems, and the software that helps machines make better decisions.

Artificial intelligence could increase the opportunity by making machines more capable in real-world settings.

This ASX ETF is likely to be volatile, but as a 10-year holding, it gives the portfolio exposure to a powerful structural theme. It was also recently recommended by analysts at Betashares.

VanEck China New Economy ETF (ASX: CNEW)

The final ASX ETF to look at is the VanEck China New Economy ETF.

This is arguably the higher-risk idea in the group.

The fund gives investors exposure to Chinese companies linked to areas such as consumer spending, healthcare, technology, industrial innovation, and other parts of the country’s changing economy.

Over a 10-year period, China’s middle class, domestic consumption, healthcare needs, digital services, and advanced manufacturing ambitions could still create strong investment opportunities.

This fund gives investors a way to access that potential without trying to pick individual Chinese shares. It was recently recommended by analysts at VanEck.

The post Where to invest $20,000 in ASX ETFs for 10 years appeared first on The Motley Fool Australia.

More reading

• Where to invest $50,000 in ASX ETFs this month
• ASX ETFs are booming. Should you join in?
• How should I invest my money in FY27?
• 3 ASX ETFs to buy and hold for 10 years
• Own NDQ, ARMR, HACK or other Betashares ASX ETFs? Dividends just announced

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) experienced a wild, and ultimately negative day of trading this Thursday, in stark contrast to yesterday’s more optimistic showing.

After some initial volatility at market open this morning, the ASX 200 spent most of the session deep in red territory. A late-afternoon rally couldn’t quite save the markets, and the index ended up closing 0.0045% lower at 8,840.7 points.

This sulky session for the ASX comes despite a more confident day over on the American markets last night.

The Dow Jones Industrial Average Index (DJX: .DJI) did well, rising 0.29%.

The tech-heavy Nasdaq Composite Index (NASDAQ: .IXIC) did even better, gaining 0.62%.

But let’s return to the local markets now and check out how the different ASX sectors navigated today’s lethargic trading conditions.

Winners and losers

Fitting with the market’s small drop, we saw a fairly even split between winners and losers this Thursday.

Leading the latter were mining shares. The S&P/ASX 200 Materials Index (ASX: XMJ) was hit hard today, cratering 1.58%.

Energy stocks had another rough one as well, with the S&P/ASX 200 Energy Index (ASX: XEJ) plunging 1.53%.

Continuing the commodities theme, gold shares came next. The All Ordinaries Gold Index (ASX: XGD) saw its value dive 0.82%.

Consumer staples stocks were on the nose too, as you can see from the S&P/ASX 200 Consumer Staples Index (ASX: XSJ)’s 0.31% dip.

Utilities shares joined the losing team, too. The S&P/ASX 200 Utilities Index (ASX: XUJ) slid down 0.21% this session.

That’s it for the losers, though, so let’s get to the green sectors. Leading the winners were communications stocks, with the S&P/ASX 200 Communication Services Index (ASX: XTJ) enjoying a 1.1% surge.

Consumer discretionary shares also ran hot. The S&P/ASX 200 Consumer Discretionary Index (ASX: XDJ) added 1.09% to its total this Thursday.

Financial shares proved popular as well. The S&P/ASX 200 Financials Index (ASX: XFJ) roared 0.88% higher.

Real estate investment trusts (REITs) fared half as well, evidenced by the S&P/ASX 200 A-REIT Index (ASX: XPJ)’s 0.44% bounce.

Healthcare stocks were right behind REITs. The S&P/ASX 200 Healthcare Index (ASX: XHJ) lifted 0.39% today.

Tech shares were in that ballpark as well, with the S&P/ASX 200 Information Technology Index (ASX: XIJ) advancing 0.38%.

Finally, industrial stocks had a lucky finish, illustrated by the S&P/ASX 200 Industrials Index (ASX: XNJ)’s 0.08% bump.

Top 10 ASX 200 shares countdown

This Thursday’s index winner was financial stock AMP Ltd (ASX: AMP). AMP shares soared 9.83% higher today to close at $1.90 each.

This big jump followed a well-received earnings update from the company.

Here’s how the other winners landed their planes: 

ASX-listed company	Share price	Price change
AMP Ltd (ASX: AMP)	$1.90	9.83%
Mesoblast Ltd (ASX: MSB)	$2.77	6.95%
REA Group Ltd (ASX: REA)	$158.71	6.61%
Tabcorp Holdings Ltd (ASX: TAH)	$0.91	5.20%
Life360 Inc (ASX: 360)	$26.52	5.03%
Lovisa Holdings Ltd (ASX: LOV)	$23.63	4.93%
IRESS Ltd (ASX: IRE)	$6.61	3.93%
Fletcher Building Ltd (ASX: FBU)	$3.13	3.64%
Washington H. Soul Pattinson and Co Ltd (ASX: SOL)	$45.49	3.32%
PEXA Group Ltd (ASX: PXA)	$7.85	3.15%

Our top 10 shares countdown is a recurring end-of-day summary that shows which companies made big moves on the day. Check in at Fool.com.au after the weekday market closes to see which stocks make the countdown.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

More reading

• 3 ASX dividend shares that look better after CGT reforms
• AMP expects higher 1H26 earnings on China growth
• Why are AMP shares trading higher today?
• Netwealth delivers record FUA in June 2026 quarter
• Could US expansion send Zip shares soaring further?

Motley Fool contributor Sebastian Bowen has positions in Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360, Lovisa, and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has positions in and has recommended Life360 and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has recommended Lovisa. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Well, it has been just over a month since the much-hyped initial public offering (IPO) of Space Exploration Technologies Corp (NASDAQ: SPCX). The IPO of Space Exploration Technologies Corp, better known as SpaceX, was perhaps the blockbuster investing event of the year. It was the largest IPO in history.

When SpaceX floated at US$135 a share last month, it valued the company at a whopping US$1.75 trillion. Despite valuation concerns, the initial float went exceedingly well for anyone who already owned SpaceX stock, or was able to secure some at US$135. After just a few days of trading, the company had rocketed (no pun intended) more than 67% to a high of US$225.64 on 16 June. That valued SpaceX at a near-inconceivable US$2.93 trillion.

Bear in mind that, as we’ve previously discussed, some investors have noted the disparity between SpaceX’s financials and the value that investors were willing to place on the company. To reiterate, the company generated US$18.7 billion in revenue last year and recorded an operating loss of US$4.2 billion.

That might explain why SpaceX stock hasn’t been doing that well since that 16 June high. In fact, SpaceX shares seem to be going in just one direction since that date a month ago. Last night (our time), the company closed at US$135.27 a share. That’s just a whisker above the initial SpaceX IPO price. What’s more, the company dipped below US$135 a share during intraday trading, hitting a low of US$132.15 (US$1.58 trillion). At that price, only investors who held shares prior to the IPO would not have been sitting on an on-paper loss.

So what’s going wrong with the SpaceX IPO then?

You might be wondering what has gone wrong with SpaceX shares since the IPO. After all, it’s not too often that a company whipsaws between US$1.58 trillion and US$2.93 trillion over just a month.

Well, I think this is a classic case of a hype bubble inflating and then deflating as excitement dies down and profits are taken off the table. We often see this happen with IPOs. The case of Guzman y Gomez Ltd (ASX: GYG) is a good local example. IPOs are, by nature, designed to maximise the profits of insider sellers, brokers, and the company itself, not to enrich retail investors. Once the rush is over, the market tends to revert to normalised valuation. And that is often bad news for those who were first to jump onto the train.

SpaceX was, and arguably still is, being priced on what it might deliver in the future, not what kind of profits it is bringing in the doors today (which were reportedly none last year). Potential is a difficult thing to price. So it’s no surprise to see the shares coming off the boil since the SpaceX IPO. I wouldn’t be surprised to see this stock continue to drift lower until we get a look at the company’s books when it reports its first set of public results. Perhaps even beyond that. Let’s see what happens to the SpaceX share price going forward.

The post What’s gone wrong with the SpaceX IPO? appeared first on The Motley Fool Australia.

More reading

• How much superannuation do I need to retire comfortably at age 67
• 3 ASX dividend shares that look better after CGT reforms
• 1 ASX dividend stock down 18% I’d buy today!
• Here’s what brokers tip for CSL shares over the next 12 months
• A miner and an energy company to buy according to Macquarie

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

When it comes to retirement, we all want to make sure we have enough superannuation to afford the best lifestyle possible. 

But working out exactly how much money you need is trickier than you’d think. 

After all, the super balance you need depends on your living situation, your expected retirement age, and what type of retirement lifestyle you’re aiming for.

Do you own your own house outright? Are you a single person or living as part of a couple? What type of travel do you expect to do after you finish working? Do you have any debts? What age do you want to retire?

Let’s assume you’re aiming for a comfortable retirement starting at age 67.

Here’s a breakdown of what that could look like, what it could cost you, and how much superannuation you’d need.

What does a comfortable retirement look like?

The Association of Superannuation Funds of Australia (ASFA) splits retirement into two broad categories: comfortable and modest.

ASFA defines a comfortable retirement as one that gives retirees a good standard of living well beyond the age pension. It budgets for expenses beyond a modest retirement, including top-tier private health insurance and regular leisure activities. It allocates funds for home repairs or renovations, and perhaps even an annual holiday.

Meanwhile, a modest retirement is defined as being able to cover expenses just slightly above what the full Centrelink Age Pension would provide from age 67. 

How much is a comfortable retirement expected to cost?

A comfortable ASFA retirement is expected to cost around $55,923 per year for single Australians, and $78,566 for a couple living together.

These figures also assume you’ll receive a part Age Pension, that you own your home in full, and that you already have an emergency fund set aside.

How much superannuation do I need at age 67 to afford that?

In order to fund a comfortable retirement, ASFA calculates that at age 67, single Australians will need around $630,000. Meanwhile, couples will need a superannuation balance of around $730,000.

How do I know if I’m on track to reach that balance by age 67?

I’ve crunched the numbers using ASFA’s super detective tool to work out what superannuation balance you should have at each age milestone to be able to reach that goal.

At age 40, Australians should have a superannuation balance of around $178,000.

By age 45, this should be closer to $239,000.

At age 50, you’ll want to have around $313,500 in your superannuation.

This should then increase to about $399,000 by age 55.

Aussies aged 60 should have close to $496,500.

By age 65, to remain on track, your total superannuation balance should be around $604,500.

Are you on track?

The post How much superannuation do I need to retire comfortably at age 67 appeared first on The Motley Fool Australia.

More reading

• 3 ASX dividend shares that look better after CGT reforms
• 1 ASX dividend stock down 18% I’d buy today!
• Here’s what brokers tip for CSL shares over the next 12 months
• A miner and an energy company to buy according to Macquarie
• How much could ResMed shares rise according to Morgans?

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

---

Capital gains tax (CGT) changes should never be a reason to throw a sound investment process in the bin.

A mediocre business does not become attractive because it pays a dividend. Nor should investors abandon companies capable of compounding capital simply because future gains may be taxed differently.

However, the announced CGT reforms could change the after-tax maths behind total shareholder returns.

Under current rules, Australian resident individuals who hold an asset for at least 12 months can generally apply a 50% discount to the taxable capital gain. If implemented as announced, the government will replace that discount from 1 July 2027 with inflation-based cost-base indexation and a minimum 30% tax rate on real gains. The new system would apply only to gains accruing after that date.

Treasury’s examples show low-return investments may pay less tax because inflation is removed from the gain. However, assets delivering strong returns above inflation can face a larger tax bill than under the current discount.

That makes it worth considering how returns are generated. Dividends remain taxable income, so they are not a free lunch. But reliable and growing distributions — particularly when supported by franking credits — may become a more valuable part of the total-return equation. The shift towards income assets is already influencing investor behaviour.

Here are three ASX dividend shares that could fit that framework.

Washington H. Soul Pattinson and Co. Ltd (ASX: SOL)

Soul Patts is not simply a high-yield stock. It is a diversified investment house designed to build wealth across market cycles.

Its portfolio spans listed companies, private businesses, emerging companies, credit, and real assets. Earlier in 2026, the company reported pre-tax net asset value of $13.8 billion, with no single asset class representing more than one-third of the portfolio.

That flexibility allows management to recycle capital into opportunities offering better risk-adjusted returns.

The dividend record is equally compelling. Soul Patts has paid a dividend every year since listing in 1903 and increased its regular dividend every year since 1998. Its latest interim dividend rose to 48 cents per share, fully franked.

For investors thinking about both capital growth and rising income, Soul Patts may be one of the ASX’s clearest all-rounders.

Transurban Group (ASX: TCL)

Transurban offers a different kind of durability.

Its toll roads are essential pieces of urban infrastructure, with revenue supported by traffic volumes and contractual toll increases. More than 90% of revenue is linked to inflation or fixed escalations, providing some protection when costs rise.

The company reported 2.6 million average daily trips in the first half of FY26, up 2.5%. Proportional revenue rose 6%, while proportional operating earnings increased 6.4%.

There are risks. Transurban carries substantial debt, making funding costs important, while toll-road regulation can create uncertainty. Even so, long-life assets, inflation-linked pricing, and growing urban congestion give it a relatively visible income base. It also adds a different income driver to a diversified dividend portfolio.

Macquarie Group Ltd (ASX: MQG)

Macquarie is often grouped with the major banks, but its earnings engine is far broader than Australian mortgages.

The group operates across asset management, commodities, infrastructure, advisory, private credit, and banking. This creates more earnings volatility than a traditional retail bank, but also reduces dependence on one economy and one lending market. It is not necessarily lower risk overall, but its risks are less concentrated in Australian housing.

Macquarie reported FY26 net profit of $4.85 billion, up 30%, and lifted its full-year dividend to $7 per share, 35% franked. The payout represented 55% of earnings, within its stated 50% to 70% policy.

An investment in Macquarie isn’t without risk. Investment banking earnings can move sharply between years. However, Macquarie’s global reach, diversified revenue streams, and conservative capital position make it an appealing dividend grower rather than a simple yield play.

Foolish takeaway

The CGT reforms should not dictate which companies investors own.

Business quality, valuation, balance-sheet strength, and future prospects still matter far more than tax settings.

However, the reforms may encourage investors to look beyond capital growth alone. Companies that can reinvest profit, grow earnings, and steadily lift dividends could offer a more balanced path to total shareholder returns.

Soul Patts, Transurban, and Macquarie each approach that task differently — through diversified capital allocation, infrastructure cash flows, and global financial expertise.

The post 3 ASX dividend shares that look better after CGT reforms appeared first on The Motley Fool Australia.

More reading

• The Macquarie share price just hit a new record high
• How much superannuation is needed to target a $100,000 annual passive income?
• How much passive income can I earn off a $50,000 portfolio?
• How to build a successful ASX dividend portfolio
• How I’d invest $10,000 in ASX shares for the next decade

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group, Transurban Group, and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has positions in and has recommended Transurban Group and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

When it comes to ASX dividend stocks, IPH Ltd (ASX: IPH) is a long-term high-yielding player.

At the time of writing, IPH shares are up around 1% and changing hands for $4.14 a piece.

The ASX dividend stock has performed well so far in 2026, climbing over 15% year to date. The share price has also rebounded an impressive 30% since hitting an all-time low of just $3.19 per share in March this year.

It hasn’t all been smooth sailing, though. The company has faced significant headwinds over the past few years, which have sent its share price crashing.

These include, underperformance by its Australia and New Zealand segments, concerns about transition to a new CEO, a declining volume of US patent filings, and currency volatility.

Since October 2022, when IPH shares spiked close to an all-time high of $9.22 a piece, they began a consistent and relentless tumble through to the end of 2025.

The most significant crash followed the company’s FY25 results in mid-August last year, when the share price fell 20% in just one day. 

So, while the year-to-date share price gains are impressive. Over the past 12 months, IPH shares are still down around 18%. 

Some investors might be put off by the falling share price and company headwinds. But I think the latest share price crash presents a rare opportunity to buy the high-yielding ASX dividend stock for cheap.

Here are three reasons why.

1. IPH has paid a reliable and consistent high-yield dividend

The ASX dividend stock has paid a regular semi-annual dividend payment to shareholders for years. IPH started paying a dividend to investors in 2016 and has gradually increased its annual payout each year since 2018.

It pays a high dividend yield, too. IPH maintains a high payout ratio of 80% to 90%. In March, the company paid its shareholders an interim dividend of 19 cents per share, 20% franked. That implies a yield of around 9.4% at the time of writing.

2. It has a defensive market position

IPH is an intellectual property (IP) services provider. Because IP protection is a legal necessity regardless of economic cycles, the company benefits from consistent cash flow and solid earnings visibility, even amid sharemarket volatility.

3. It has secured new executive leadership

Part of the headwinds facing IPH has been uncertainty about the company’s ability to transition its leadership to a new CEO. 

But in May, the company announced it had recruited for the position, and Tony O’Malley began the role as Managing Director and Chief Executive Officer earlier this month. 

He replaced Andrew Blattman, who flagged his retirement in November. Blattman will stay with the company for a transition period and continue providing support until 30 November 2026.

The update has clearly helped to ease some investor concerns and improve sentiment.

The post 1 ASX dividend stock down 18% I’d buy today! appeared first on The Motley Fool Australia.

More reading

• How much passive income can I earn off a $50,000 portfolio?
• How much do I need in my superannuation to get $50k per year in passive income?
• 2 ASX dividend shares that yield 9% (or even higher)
• How much do I need in my superannuation to get $6,000 per month in passive income?
• How much do I need in superannuation to receive $5,500 per month in passive income?

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended IPH Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares are climbing higher into the green in Thursday lunchtime trade.

At the time of writing, the shares are up around 0.5% and changing hands for $122.29 a piece.

Today’s uptick means the ASX biotech shares have now climbed around 15% over the past month and have rebounded 33% since a 15-year low in early June.

But there is still a long way for CSL shares to go before they’ve recouped the huge amount of losses shed over the past 18 months.

The shares are still down around 29% for the year-to-date and are 51% lower than trading prices 12 months ago.

The latest rebound is certainly a step in the right direction. But the question now is, can CSL shares keep climbing higher?

Here’s what the experts expect from the biotech stock over the next 12 months.

Buy, sell or hold: Here’s what brokers tip for CSL shares

It looks like market sentiment for CSL shares has shifted recently. Previously, brokers were incredibly bullish about the ASX healthcare shares and were confident of a strong upside ahead.

But now it looks like there’s a little more caution in the market.

Market Index data shows that the majority of brokers now have a hold rating on CSL shares. The $131.48 target price implies a potential 8% upside at the time of writing.

TradingView data also shows some ratings downgrades. Out of 18 analysts, 10 now have a hold stance on the biotech company’s shares, and another eight have a hold or strong hold rating.

The average target price is a little higher at $140.15, which implies a potential 15% upside at the time of writing. But some are still bullish that CSL shares could climb 64% to $199.68 over the next 12 months.

Morgans is one of the more optimistic brokers. It has a buy rating with a price target of $147.59, implying a robust upside ahead. The broker notes that CSL’s long-term story remains intact. However, it thinks that a sustained recovery in sentiment may take several quarters to fully materialise while investors wait for clear improvement in the company’s financials.

Elsewhere, the team at Macquarie is more cautious. The broker has a lower price target of $114 and a neutral stance. It cites uncertainty across CSL’s core plasma and albumin businesses, as well as ongoing competitive pressures.

My view on CSL shares

The latest rebound shows that investors are now looking forward to the company’s FY26 results announcement and any sign that management has been able to improve operations. 

I think there is a lot of potential for the company over the next few years. After all, CSL is operating in a high-growth market, and its blood plasma division dominates the market for rare blood disorders and immunoglobulin products. 

Global demand for plasma therapies is strong and growing, too. There is recurring demand and limited competition, which makes CSL well-placed to carve out a significant portion of the market.

I think that once CSL is able to turn around its financials, investor confidence will follow.

The post Here’s what brokers tip for CSL shares over the next 12 months appeared first on The Motley Fool Australia.

More reading

• How have CSL shares performed over 10 years?
• The Macquarie share price just hit a new record high
• How I’d invest $10,000 in ASX shares for the next decade
• What did the market look like 10 years ago? Here’s what’s changed for the ASX 200
• Would Warren Buffett buy CSL shares?

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has recommended CSL and Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The analyst team at Macquarie has recently issued new research notes on various companies in the resources sector.

I’ve picked out two ASX shares which might be of interest, respectively in the gas and mineral sands sectors.

Let’s have a look at who they like.

Amplitude Energy Ltd (ASX: AEL)

Macquarie notes in its recent report on Amplitude that the company is on track for a final investment decision for its East Coast Gas Project this quarter and first production in FY28.

Amplitude shored up the project in May, buying half of the Artisan gas field in the offshore Otway Basin from Beach Energy Ltd (ASX: BPT) for $58.3 million.

Amplitude Managing Director Jane Norman said regarding the deal:

Producing Artisan through Amplitude Energy’s existing infrastructure allows faster and lower-cost development of this gas for the east coast domestic market. Artisan development costs will significantly benefit from leveraging the existing East Coast Supply Project (ECSP) program and our readily-available infrastructure. This is a win-win for Amplitude, O.G. Energy and Beach with respect to optimising our respective Otway Basin positions. We expect to rapidly move to FID on the development phase of the ECSP over the next few months while the drilling of the Juliet and Annie wells is conducted, with Juliet now brought forward and drilling expected to commence by late July or early August.

Macquarie said there was downside pressure on gas prices from the Federal Government’s gas reservation scheme, but also noted that 80% of Amplitude’s 2026 gas volumes were under contract.

They added:

Latest gas market interventions drive a structural oversupply in domestic gas markets, but we believe incentives may ultimately be required to encourage investment in backfill supply projects (eg. carve outs, subsidies, creation of domestic trading credit market).

Macquarie has a price target of $2.15 on Amplitude shares compared to $1.49 currently.

Iluka Resources Ltd (ASX: ILU)

Macquarie said zircon pricing improved in the first quarter of 2026, with improved Chinese sentiment and tight premium zircon supply supporting the market.

In contrast, titanium dioxide markets remained weak, while rutile prices were also depressed through the second quarter, Macquarie said.

Despite that weakness, Macquarie has a bullish share price target on the stock of $8 compared to $6.30 currently.

The broker added:

While we see early signs of recovery in zircon markets, titanium dioxide feedstock markets remain weak and continue to present an earnings headwind for ILU. Construction of Eneabba Phase 3 remains underway, with completion targeted for 2HCY27, requiring investors to maintain a longer-term investment horizon.

The post A miner and an energy company to buy according to Macquarie appeared first on The Motley Fool Australia.

More reading

• Why this ASX energy stock could be set to rise 80%: Expert
• 2 ASX growth shares with strong potential to buy
• Amplitude Energy shares could be set to soar 90%: Expert
• Are these oversold ASX shares too good to pass up?
• This ASX gas company could more than double in value: Broker

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ResMed Inc (ASX: RMD) shares have fallen by more than 25% over the past year, which begs the question: Is now the time to buy in?

ResMed shares looking cheap according to analysts

The analyst team at Morgans has run the ruler over the company, and has a buy recommendation on the stock and a bullish share price target, which we’ll get to shortly.

The reason the Morgans team had another look at ResMed was because of the company’s recent move to sell its MatrixCare division for US$490 million, with that sale expected to be completed in the first quarter of FY27.

ResMed said the sale would allow it to focus more strongly on its core business.

As it said:

This move reflects Resmed’s 2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcare. The divestiture also strengthens Resmed’s ability to reallocate capital and resources toward innovation, operational scale and long-term value creation across its connected, home-based care ecosystem.

MatrixCare is a software business focused on “nursing, senior living and long-term care, life planning communities, and home health and hospice care”.

The Morgans team said they believed the transaction made sense as it would simplify the ResMed business.

They added:

Importantly, net proceeds will largely be returned to shareholders via an accelerated share repurchase (ASR), which should substantially offset earnings dilution from both the MatrixCare disposal and the recently completed Noctrix acquisition, while FY26 guidance has been reaffirmed.

Morgans said MatrixCare, which ResMed acquired for US$750 million in 2018, had been a disappointing acquisition for the company.

Morgans said:

During this time, earnings increased from ~US$30m to ~US$55m, implying modest long-term earnings growth. While this reflects poorly on the original acquisition, we believe exiting today is preferable to continuing to allocate capital toward a mature business with limited strategic alignment.

ResMed target price has been reduced

Overall, Morgans remains positive on ResMed’s outlook; however, they slightly reduced their price target to $41.72.

As they said:

We view RMD’s fundamentals as sound, with consistent execution, strong cash generation and structural growth tailwinds from expanding diagnosis and resupply. We have a BUY rating with a sum of the parts/discounted cash flow target price of $40.97.

ResMed shares were changing hands for $28.25 on Thursday.

The company is valued at $40.06 billion and pays an unfranked 1.23% dividend yield.

ResMed will report its fourth quarter earnings on 6 August.

The post How much could ResMed shares rise according to Morgans? appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Pro Medicus, Worley, and ResMed shares
• 3 ways to get from $100,000 to $500,000 in retirement savings
• 5 things to watch on the ASX 200 on Thursday
• How I’d invest $10,000 in ASX shares for the next decade
• 10 fantastic ASX shares to buy for FY27

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.